# Comparative study of dulaglutide single-use pen Ateos versus insulin degludec FlexTouch on learning and mock administration time in Japanese patients with type 2 diabetes mellitus - a post-hoc analys…

> PubMed lists PMID 32141343 in Current medical research and opinion as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-03-19 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32141343-dulaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-03-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32141343-dulaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-32141343-dulaglutide-v1.json
- Content SHA-256: `1d5a6102da29eaf8e3fe9721e2619916ed93ae59db4db9eed2706cd2f5160be3`

## Claims and source pins

### Headline

Comparative study of dulaglutide single-use pen Ateos versus insulin degludec FlexTouch on learning and mock administration time in Japanese patients with type 2 diabetes mellitus - a post-hoc analys… ([`pubmed-observation-pmid-32141343-2021-03-11-7452eedf35fd`](#source-pubmed-observation-pmid-32141343-2021-03-11-7452eedf35fd))

### Summary

PubMed lists PMID 32141343 in Current medical research and opinion as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-03-19 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32141343-2021-03-11-7452eedf35fd`](#source-pubmed-observation-pmid-32141343-2021-03-11-7452eedf35fd))

### Paragraph 1

PubMed lists PMID 32141343 in Current medical research and opinion as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-03-19 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32141343-2021-03-11-7452eedf35fd`](#source-pubmed-observation-pmid-32141343-2021-03-11-7452eedf35fd))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32141343-2021-03-11-7452eedf35fd`](#source-pubmed-observation-pmid-32141343-2021-03-11-7452eedf35fd))

## Sources

<a id="source-pubmed-observation-pmid-32141343-2021-03-11-7452eedf35fd"></a>
- **Comparative study of dulaglutide single-use pen Ateos versus insulin degludec FlexTouch on learning and mock administration time in Japanese patients with type 2 diabetes mellitus - a post-hoc analysis. · retained source version 1:2021-03-11:current:7452eedf35fdd99847e07c9f4c6dd02073fe2ae10d60fc7c3f739fe290f936b7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32141343/) (`pubmed-observation-pmid-32141343-2021-03-11-7452eedf35fd`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Comparative study of dulaglutide single-use pen Ateos versus insulin degludec FlexTouch on learning and mock administration time in Japanese patients with type 2 diabetes mellitus - a post-hoc analys…." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-32141343-dulaglutide-v1.json SHA-256: 1d5a6102da29eaf8e3fe9721e2619916ed93ae59db4db9eed2706cd2f5160be3.